Specialty pharmaceutical firm Akorn (AKRX) finishes the day up over 10% after its Q3 easily...


Specialty pharmaceutical firm Akorn (AKRX) finishes the day up over 10% after its Q3 easily beats estimates. Revenue jumped 69% Y/Y on higher sales and the continued growth of its injectable and ophthalmic products launched in 2010. Gross margin rose to 60% due to a favorable product mix, price increases and more efficient plant utilization.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs